AmCAD-UO
AmCad BioMed Corporation • Radiology • 12/28/2018
Device Purpose
AmCAD-UO is a software application designed for the analysis of pharyngeal/upper airway ultrasonic images, utilizing tools for manual or interactive Region of Interest selection. It provides visualization and quantification of airway sonographic characteristics, such as size and position, to aid physicians in evaluating and monitoring the airway state.
Summary
AmCAD-UO is a PC-based, non-invasive image analysis software application designed to review ultrasonic images of the pharyngeal and upper airway. Its primary purpose is to support clinicians in visualizing and quantifying the sonographic characteristics of the airway. The software processes images acquired from an FDA-cleared ultrasound system, allowing for detailed examination of airway structures. The methodology involves tools for either manual or interactive selection of a Region of Interest (ROI) within the ultrasonic image. Once an ROI is defined, AmCAD-UO analyzes the airway in terms of its size, position, and enhancement pattern. This analysis provides objective data intended to assist physicians in their evaluation and ongoing monitoring of a patient's airway condition, contributing to informed clinical decision-making.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. What specific quantitative metrics for airway size, position, and enhancement patterns does AmCAD-UO provide, and what are their validated ranges of accuracy?; How does AmCAD-UO address potential variabilities in ultrasound image quality or acquisition technique from different FDA-cleared ultrasound systems?; What is the learning curve for clinicians to become proficient in using the manual and interactive Region of Interest selection tools effectively?; Are there any known contraindications or patient populations for whom the AmCAD-UO analysis might be less reliable or not applicable?; How does the 'enhancement pattern' analysis contribute to the physician's evaluation, and what specific patterns are identified?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, ML-BOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly